List of Excipients in Branded Drug BUPROPION HYDROCHLORIDE (SR)

Generic Drugs Containing BUPROPION HYDROCHLORIDE (SR)

Company	Ingredient	NDC	Excipient
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	ACACIA
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	ALCOHOL
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	CELLULOSE, MICROCRYSTALLINE
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	COPOVIDONE K25-31
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	CYSTEINE HYDROCHLORIDE
Dr Reddy's Laboratories Inc	bupropion hydrochloride	43598-863	DEXTROSE

What are the Most Frequently-Used Excipients in BUPROPION HYDROCHLORIDE (SR)?

# Of NDCs	Excipient
1	ACACIA
1	ACACIA SENEGAL GUM
2	ALCOHOL
10	CELLULOSE, MICROCRYSTALLINE
2	COPOVIDONE K25-31
1	CURRY RED

Bupropion Hydrochloride Sustained-Release Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Bupropion hydrochloride sustained-release, commonly marketed as bupropion HCl SR, is a mature generic product with commercial opportunity concentrated in formulation reliability, manufacturing efficiency, supply security, and differentiated patient use rather than basic compound exclusivity. The critical technical problem is controlled release of a highly soluble drug while limiting rapid exposure, variability between tablets, and dose dumping. Excipient selection must support dissolution control, tablet robustness, content uniformity, stability, and bioequivalence.

What is the commercial market for bupropion hydrochloride SR?

Bupropion HCl SR is approved primarily for major depressive disorder and smoking cessation. Wellbutrin SR is associated with depression treatment, while Zyban is associated with smoking cessation. Generic products are marketed in 100 mg, 150 mg, and 200 mg sustained-release strengths in the United States, although product availability varies by manufacturer and time.

Parameter	Commercial relevance
Active ingredient	Bupropion hydrochloride
Release type	Sustained release, generally dosed twice daily
Common strengths	100 mg, 150 mg, 200 mg
Reference products	Wellbutrin SR and Zyban
Main therapeutic uses	Major depressive disorder; smoking cessation
Primary U.S. pathway	Abbreviated New Drug Application, or ANDA
Main technical risk	Dissolution and pharmacokinetic variability
Key safety constraint	Dose-related seizure risk
Main commercial buyers	Retail pharmacies, wholesalers, health systems, government purchasers, contract distributors
Differentiation potential	Excipients, tablet robustness, packaging, supply reliability, private label, and alternative dosage forms

Bupropion is commercially attractive because demand spans psychiatric treatment and smoking cessation. The market is mature, but chronic use creates recurring volume. A manufacturer can compete through lower cost, reliable availability, fewer recalls, improved tablet handling, and consistent substitution performance.

What excipients are used in bupropion hydrochloride SR tablets?

The reference and generic products use matrix-forming, compression, coating, and processing excipients. Exact inactive ingredients vary by manufacturer and strength.

Excipient category	Typical examples	Primary function
Hydrophilic matrix former	Hypromellose	Controls water penetration and drug diffusion
Diluent or compression aid	Microcrystalline cellulose	Provides tablet mass, compactability, and mechanical strength
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces manufacturing variability
Lubricant	Magnesium stearate or comparable lubricant	Reduces ejection force and tooling adhesion
Granulation or binder system	Hypromellose, povidone, or starch-based binder	Improves granule strength and content uniformity
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Protects the tablet and supports identification
Plasticizer	Polyethylene glycol or triethyl citrate	Improves coating flexibility
Opacifier or pigment	Titanium dioxide, iron oxides, approved colorants	Provides appearance and light protection
Release-modifying excipients	Higher-viscosity hypromellose, waxes, hydrophobic polymers	Adjusts release rate and sensitivity to agitation

The commercial target is not simply a slower dissolution curve. The formulation must reproduce the reference product's release behavior across multiple dissolution conditions and demonstrate acceptable pharmacokinetics in the required bioequivalence studies.

How does the excipient system control bupropion SR release?

Bupropion hydrochloride has high aqueous solubility. A conventional immediate-release tablet can produce rapid exposure, which is unsuitable for the sustained-release product. The formulation therefore must create a reproducible barrier to liquid ingress and drug diffusion.

Hydrophilic matrix strategy

Hypromellose is the most commercially practical release-control excipient for a conventional hydrophilic matrix. Upon hydration, it forms a viscous gel layer. Release is governed by a combination of:

• Water penetration into the matrix
• Polymer hydration and swelling
• Drug dissolution
• Diffusion through the gel layer
• Erosion of the hydrated matrix

The grade and viscosity of hypromellose materially affect release. A low-viscosity grade may release drug too quickly. A high-viscosity grade may produce excessive retardation or a release profile that diverges from the reference product.

Hydrophobic matrix strategy

Hydrophobic excipients such as waxes or certain lipid-based materials can reduce water penetration. They may improve resistance to rapid dissolution, but they can complicate content uniformity, granulation, scale-up, and dissolution matching. Their use is more commercially relevant where the developer seeks a robust release barrier or a differentiated manufacturing process.

Coating strategy

A film coat generally does not provide the primary sustained-release function in a conventional bupropion SR tablet. Its role is usually protection, identification, swallowability, and control of surface defects. A coating that materially delays release can increase development risk because it may create a release profile different from the reference product or introduce sensitivity to coating weight and curing conditions.

What formulation attributes are most important for bupropion SR?

The highest-value critical quality attributes are dissolution, assay, content uniformity, tablet hardness, friability, impurities, and stability.

Critical quality attribute	Why it matters
Dissolution at multiple time points	Establishes sustained-release performance and supports ANDA bioequivalence
Dose uniformity	Controls patient exposure and seizure-related safety risk
Tablet hardness	Affects mechanical integrity and release
Friability	Determines resistance to chipping and breakage
Disintegration behavior	Prevents unintended rapid drug release
Moisture content	Affects polymer hydration, compression, and stability
Related substances	Controls degradation and process-related impurities
Coating integrity	Reduces damage, identification errors, and handling loss
Stability under heat and humidity	Determines shelf life and packaging requirements

A formulation that meets a single dissolution specification but performs poorly under agitation, compression stress, or scale-up conditions may still create commercial problems. Robustness across manufacturing lots has greater value than a narrow laboratory optimum.

What excipient strategy is most attractive for a generic manufacturer?

A conventional hydrophilic matrix is usually the lowest-risk starting point. The preferred strategy is to use well-characterized, widely available excipients with established pharmaceutical use and predictable supply.

Recommended base formulation approach

A commercial development program should typically evaluate:

1. Hypromellose grade and concentration as the primary release-control variables.
2. Microcrystalline cellulose level to balance tablet size and compactability.
3. Binder concentration to control granule strength and content uniformity.
4. Lubricant level and blending time because over-lubrication can weaken tablets and alter dissolution.
5. Granulation endpoint and drying conditions because residual moisture affects matrix performance.
6. Compression force because hardness can change liquid ingress and release.
7. Film-coating weight and curing conditions where applicable.

The formulation should use design-of-experiments work to map the relationship between polymer viscosity, polymer load, tablet hardness, granule moisture, and dissolution. The objective is a broad acceptable operating region rather than one optimized batch.

Excipient supply strategy

Supply-chain risk is commercially significant for a mature generic. A manufacturer should qualify at least two sources for critical excipients where the regulatory filing permits it and should evaluate supplier changes against the approved composition and quality system.

The most important supply controls include:

• Dual sourcing for hypromellose and microcrystalline cellulose
• Defined particle-size and viscosity specifications
• Control of magnesium stearate surface area and fatty-acid profile
• Supplier change notification requirements
• Verification of compendial compliance
• Monitoring of elemental impurities and microbiological quality
• Reserve inventory for high-volume strengths

Supplier changes can affect dissolution even when the excipient name and compendial grade remain unchanged. Polymer viscosity, particle morphology, bulk density, and moisture can shift manufacturing behavior.

What FDA regulatory requirements apply to bupropion SR?

Bupropion HCl SR generics generally proceed through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference listed drug.

FDA's requirements typically include:

• Same active ingredient and dosage form
• Same strength
• Comparable route of administration
• Pharmaceutical equivalence
• In vitro dissolution comparison
• In vivo pharmacokinetic bioequivalence where required
• Stability data
• Manufacturing and controls information
• Labeling that is consistent with the reference product, subject to permitted generic differences

FDA's product-specific guidance for bupropion hydrochloride extended-release tablets identifies dissolution and pharmacokinetic evaluation as important development considerations. Extended-release products may require studies under fasting and fed conditions, and applicants must assess whether food changes exposure or release behavior in a clinically meaningful manner (FDA, n.d.-a).

A formulation with a new excipient, unusual release technology, or substantial labeling distinction may create a 505(b)(2) or new drug application issue rather than a straightforward ANDA path.

What safety issues influence bupropion SR formulation design?

Bupropion has a dose-related seizure risk. The label limits individual doses and establishes minimum intervals between doses. The sustained-release formulation is designed to avoid excessive peak concentrations and rapid release.

The formulation must therefore avoid:

• Rapid release after tablet fracture
• Excessive sensitivity to alcohol or high agitation
• Significant release acceleration after mechanical damage
• Large lot-to-lot changes in dissolution
• Confusion between sustained-release and immediate-release products
• Inadequate control of tablet strength

The label instructs patients to swallow sustained-release tablets whole and not to crush, chew, or divide them. This makes tablet integrity, labeling, and patient-facing packaging important commercial controls (FDA, 2024a; FDA, 2024b).

What Orange Book and patent issues affect bupropion SR?

Bupropion HCl SR is a mature product category. The original Wellbutrin SR and Zyban market protections have expired, and generic competition has been established for many years. The commercial barrier is therefore regulatory execution and manufacturing performance rather than an unexpired basic active-ingredient patent.

The Orange Book remains relevant for:

• Identifying the reference listed drug
• Reviewing current patent and exclusivity information
• Confirming therapeutic equivalence evaluations
• Assessing whether a particular strength or formulation has listed patents
• Reviewing applicant certifications and product-specific regulatory status

Applicants should review the current FDA Orange Book and patent listing records before filing because listed information can change by product, strength, dosage form, and sponsor (FDA, n.d.-b).

Paragraph IV challenge risk

For a mature bupropion SR product, Paragraph IV risk is usually lower than for a recently launched drug because foundational patents have expired and multiple generic products already exist. The remaining risks may involve:

• A formulation patent covering a specific matrix or coating
• A method-of-use patent
• A later-listed patent associated with a modified dosage form
• Litigation over product-specific claims
• Regulatory exclusivity tied to a new formulation or indication

A new applicant should not assume that absence of a basic compound patent eliminates all filing risk. The relevant analysis must be performed against the current Orange Book listings and the exact proposed product.

What commercial opportunities exist beyond standard generic tablets?

Private-label and institutional supply

Retail and institutional buyers may value reliable supply more than minor formulation differentiation. A manufacturer with excess capacity can pursue private-label arrangements, health-system contracts, and wholesaler programs.

Supply-secure positioning

Bupropion products have experienced periodic shortages and manufacturer-specific availability issues. A supplier with validated second-source excipients, redundant manufacturing capacity, and adequate safety stock can compete for contracts that prioritize continuity.

Packaging differentiation

Packaging can reduce dispensing errors between:

• Bupropion immediate-release tablets
• Bupropion SR tablets
• Bupropion XL tablets
• Depression and smoking-cessation branded products

Unit-dose blister packaging may be attractive for institutional settings and smoking-cessation programs. Child-resistant bottles remain standard for retail distribution.

Manufacturing-cost reduction

The largest cost opportunities may arise from:

• Direct compression, if blend uniformity and release control are adequate
• High-shear wet granulation with optimized endpoint control
• Reduced coating weight
• Fewer manufacturing steps
• Improved tablet yield
• Lower tooling wear
• Reduced overage and rejection rates

Direct compression has lower process complexity but may increase segregation and dissolution risk. Wet granulation can improve content uniformity and compressibility but adds drying and scale-up variables.

Alternative delivery systems

A new bupropion product using an alternative release technology, abuse-deterrent design, or modified dosing schedule could pursue a 505(b)(2) strategy. The commercial case would need to justify the additional clinical, regulatory, and patent costs. A new delivery system would not automatically qualify for ANDA treatment.

How does bupropion SR compare with bupropion XL and immediate-release products?

Attribute	Immediate-release	Sustained-release	Extended-release
Typical dosing pattern	More frequent dosing	Usually twice daily	Usually once daily
Release control	Minimal	Matrix or equivalent controlled release	Longer-duration release system
Main formulation challenge	Rapid exposure control	Reproducible release and dose spacing	Extended release over a longer interval
Generic competition	Mature	Mature	Mature but technically more complex
Excipient emphasis	Compression and stability	Matrix polymer and dissolution	Multiphase or advanced release control
Main commercial differentiator	Cost and availability	Reliable dissolution and tablet integrity	Convenience and formulation performance

An SR formulation cannot be treated as a simple intermediate between immediate-release and XL products. Each dosage form has its own reference product, bioequivalence requirements, labeling, and formulation risks.

How strong is the patent estate for bupropion SR?

The basic patent estate is commercially weak because the product is mature and genericized. The potentially relevant protection is more likely to arise from formulation-specific or process-specific claims than from the bupropion molecule itself.

Patent category	Expected commercial importance
Compound patent	Low for current generic entry
Basic therapeutic-use patent	Low for established indications
SR matrix formulation	Potentially relevant if still listed and enforceable
Coating or release-control technology	Relevant only to the claimed implementation
Manufacturing process	Can create operational advantages, but may be difficult to detect or enforce
Packaging or device claims	Limited relevance for conventional tablets
New indication claims	Potentially relevant to branded 505(b)(2) products

Patent strength should be assessed claim by claim. A narrow claim covering a specific polymer ratio may not block a generic using a different matrix system. A broad formulation claim may be more valuable but is also more vulnerable to validity and written-description challenges.

What generic launch scenarios exist for bupropion SR?

Low-cost conventional launch

This is the most realistic scenario. The applicant uses a conventional hypromellose matrix, demonstrates bioequivalence, and competes through price, supply reliability, and distribution.

Premium reliability launch

A manufacturer can target institutional purchasers with documented supply continuity, dual-source excipients, low lot-release variability, and packaging that reduces product confusion.

Private-label launch

A contract manufacturer supplies a distributor or pharmacy chain under a private label. The main requirements are competitive cost, regulatory compliance, and predictable capacity.

Differentiated reformulation

A new release technology, lower tablet burden, or specialized packaging may create a 505(b)(2) opportunity. This route carries higher development expense and may face new patent barriers.

What are the main commercial risks?

The principal risks are:

• Failure to match the reference dissolution profile
• Bioequivalence failure caused by food or formulation effects
• Manufacturing drift after scale-up
• Excipient supplier changes
• Product recalls related to dissolution or potency
• Confusion among IR, SR, and XL products
• Price erosion from multiple generic competitors
• Limited ability to protect a conventional formulation with new patents
• Low margins in tender and wholesaler channels

Revenue exposure is highest for manufacturers that rely on a single strength, single site, or single excipient supplier. A portfolio covering 100 mg, 150 mg, and 200 mg strengths can improve customer retention and manufacturing utilization, but each strength may require separate dissolution and stability control.

Key Takeaways

• Bupropion HCl SR is a mature, genericized product with limited compound-patent protection.
• The most practical formulation uses a hydrophilic matrix, commonly based on hypromellose.
• Dissolution control, tablet integrity, and dose uniformity are the central technical priorities.
• Excipient variability can alter release even when the nominal formulation remains unchanged.
• Commercial opportunity is strongest in supply reliability, manufacturing efficiency, private label, institutional contracts, and packaging.
• A conventional generic normally follows the ANDA pathway; a materially different delivery system may require a 505(b)(2) strategy.
• Patent risk should be reviewed against current Orange Book listings and the exact dosage form and strength.
• Bupropion's seizure-related safety profile increases the importance of preventing dose dumping and rapid exposure.
• The strongest generic business case is a low-cost, reliable, multi-strength product with robust dissolution performance.

FAQs

Can hypromellose be replaced with another release-controlling excipient in bupropion SR?

Yes, but the replacement must reproduce the reference product's release and pharmacokinetic performance. A different polymer can increase development, dissolution, and regulatory risk.

Is bupropion SR suitable for direct compression?

It may be suitable if powder flow, segregation control, content uniformity, tablet strength, and dissolution are acceptable. Wet granulation may provide greater process control when the drug load or powder properties create manufacturing problems.

Can bupropion SR tablets be scored?

Scoring is a product-specific attribute. A scored tablet must meet relevant FDA requirements for dose uniformity and splitting, and patients must not be instructed to split the tablet unless the approved labeling permits it.

Do excipient changes require a new FDA application?

The regulatory consequence depends on the nature and extent of the change, its effect on product quality, and the applicable postapproval change guidance. A change may require notification, prior approval, or a supplement.

Is an abuse-deterrent bupropion SR product commercially attractive?

It could be commercially attractive only if the technology addresses a defined clinical or payer need and supports a viable regulatory and reimbursement strategy. The added formulation and clinical burden would be substantial for a mature low-cost generic.

References

1. U.S. Food and Drug Administration. (2024a). Wellbutrin SR (bupropion hydrochloride) sustained-release tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024b). Zyban (bupropion hydrochloride) sustained-release tablets prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.-a). Product-specific guidances for generic drug development. FDA.

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. FDA.

6. U.S. Food and Drug Administration. (2014). Guidance for industry: SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. FDA.